SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-22-019858
Filing Date
2022-05-12
Accepted
2022-05-12 16:10:32
Documents
14
Period of Report
2022-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K trvi-8k_20220512.htm   iXBRL 8-K 42148
2 EX-99.1 trvi-ex991_6.htm EX-99.1 106393
3 GRAPHIC gdpiq00nc1zg000001.jpg GRAPHIC 29443
  Complete submission text file 0001564590-22-019858.txt   331809

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA trvi-20220512.xsd EX-101.SCH 5729
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE trvi-20220512_lab.xml EX-101.LAB 20173
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE trvi-20220512_pre.xml EX-101.PRE 12061
8 EXTRACTED XBRL INSTANCE DOCUMENT trvi-8k_20220512_htm.xml XML 3687
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

IRS No.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38886 | Film No.: 22917891
SIC: 2834 Pharmaceutical Preparations